Flamsa-RIC Sequential Regimen in High Risk CR1 AML Patients: Preliminary Results From a Pilot Study
Marie Y. Detrait(Hôpital Civil de Charleroi), Mauricette Michallet(Université Claude Bernard Lyon 1), Vérane Schwiertz(Hospices Civils de Lyon), Nathalie Tedone(Hospices Civils de Lyon), Sothiny Sar(Hôpital Lyon Sud), Stéphane Morisset(Lyon 1 Université), Valérie Chapelle(Hôpital Lyon Sud), Fiorenza Barraco(Hôpital Lyon Sud), Catherine Rioufol(Lyon 1 Université), Youcef Chelghoum(Hôpital Edouard Herriot), Xavier Thomas(Hôpital Lyon Sud), Adrien Quintela(Hospices Civils de Lyon), Isabelle Tigaud(Inserm), Franck E. Nicolini(Université Claude Bernard Lyon 1), Hélène Labussière‐Wallet(Hospices Civils de Lyon), Mohamad Sobh(Ottawa Hospital), Jean‐Pierre Magaud(Hôpital Lyon Sud), Florence Ranchon(Lyon 1 Université), Sandrine Hayette(Hôpital Claude Huriez), Sophie Ducastelle(Hôpital Lyon Sud)
Cited by 0
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547